Ethical Challenges of Risk, Informed Consent, and Posttrial Responsibilities in Human Research With Neural Devices: A Review.
Journal
JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536
Informations de publication
Date de publication:
01 Dec 2019
01 Dec 2019
Historique:
medline:
18
10
2019
pubmed:
18
10
2019
entrez:
18
10
2019
Statut:
ppublish
Résumé
Developing more and better diagnostic and therapeutic tools for central nervous system disorders is an ethical imperative. Human research with neural devices is important to this effort and a critical focus of the National Institutes of Health Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative. Despite regulations and standard practices for conducting ethical research, researchers and others seek more guidance on how to ethically conduct neural device studies. This article draws on, reviews, specifies, and interprets existing ethical frameworks, literature, and subject matter expertise to address 3 specific ethical challenges in neural devices research: analysis of risk, informed consent, and posttrial responsibilities to research participants. Research with humans proceeds after careful assessment of the risks and benefits. In assessing whether risks are justified by potential benefits in both invasive and noninvasive neural device research, the following categories of potential risks should be considered: those related to surgery, hardware, stimulation, research itself, privacy and security, and financial burdens. All 3 of the standard pillars of informed consent-disclosure, capacity, and voluntariness-raise challenges in neural device research. Among these challenges are the need to plan for appropriate disclosure of information about atypical and emerging risks of neural devices, a structured evaluation of capacity when that is in doubt, and preventing patients from feeling unduly pressured to participate. Researchers and funders should anticipate participants' posttrial needs linked to study participation and take reasonable steps to facilitate continued access to neural devices that benefit participants. Possible mechanisms for doing so are explored here. Depending on the study, researchers and funders may have further posttrial responsibilities. This ethical analysis and points to consider may assist researchers, institutional review boards, funders, and others engaged in human neural device research.
Identifiants
pubmed: 31621797
pii: 2752422
doi: 10.1001/jamaneurol.2019.3523
pmc: PMC9395156
mid: NIHMS1811494
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1506-1514Subventions
Organisme : Intramural NIH HHS
ID : Z99 CL999999
Pays : United States
Références
Arch Neurol. 2011 Feb;68(2):165
pubmed: 20937936
Int J Law Psychiatry. 1982;5(3-4):319-29
pubmed: 6135666
Hastings Cent Rep. 2016 Nov;46(6):14-24
pubmed: 27875647
Lancet Neurol. 2009 Jan;8(1):67-81
pubmed: 19081516
Front Neurosci. 2018 May 29;12:360
pubmed: 29896085
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Handb Clin Neurol. 2013;118:315-21
pubmed: 24182388
JAMA Neurol. 2017 Jan 1;74(1):9-10
pubmed: 27820615
Arch Gen Psychiatry. 2010 May;67(5):507-16
pubmed: 20439832
JAMA Neurol. 2013 Feb;70(2):163-71
pubmed: 23407652
Neurotherapeutics. 2014 Jul;11(3):553-63
pubmed: 24850309
Ann Neurol. 2016 Jul;80(1):1-4
pubmed: 27216434
J Neurosci. 2018 Dec 12;38(50):10586-10588
pubmed: 30541767
Pacing Clin Electrophysiol. 1986 Nov;9(6):1181-5
pubmed: 2432529
Neurology. 2006 Jun 27;66(12):1811-6
pubmed: 16801642
Cell. 2016 Nov 3;167(4):882-885
pubmed: 27814514
Arch Gen Psychiatry. 2009 Sep;66(9):931-7
pubmed: 19736349
J Med Ethics. 2008 Sep;34(9):e1
pubmed: 18757609
Expert Rev Med Devices. 2014 Nov;11(6):563-72
pubmed: 25141960
JAMA. 2000 May 24-31;283(20):2701-11
pubmed: 10819955
Eur J Neurosci. 2010 Oct;32(7):1152-62
pubmed: 21039955
Int J Obes (Lond). 2017 Dec;41(12):1721-1727
pubmed: 28663570
J Physiol Paris. 2016 Nov;110(4 Pt A):392-401
pubmed: 28756027
Thorac Surg Clin. 2005 Nov;15(4):555-63, viii
pubmed: 16276820
Neurosurgery. 2018 Jul 1;83(1):29-37
pubmed: 28973530
Neuron. 2016 Dec 7;92(5):943-948
pubmed: 27930909
J Clin Neurosci. 2015 Oct;22(10):1537-43
pubmed: 26122383
Clin Neurophysiol. 2017 Sep;128(9):1774-1809
pubmed: 28709880
J Neurosurg. 2014 Jan;120(1):132-9
pubmed: 24236657
Camb Q Healthc Ethics. 2018 Apr;27(2):316-325
pubmed: 29509128
Neuropsychopharmacology. 2010 Jan;35(1):301-16
pubmed: 19693003
Public Health Ethics. 2011 Jul;4(2):160-184
pubmed: 21754950
Med Care. 2002 Sep;40(9 Suppl):V55-63
pubmed: 12226586
Am J Bioeth. 2015;15(4):80-2
pubmed: 25856617
J Law Biosci. 2015 Oct 12;2(3):669-696
pubmed: 27774217
Mol Psychiatry. 2012 Jun;17(6):572-83
pubmed: 21931318
IRB. 2009 Nov-Dec;31(6):10-4
pubmed: 20034185
Yale J Health Policy Law Ethics. 2008 Winter;8(1):37-92
pubmed: 18564493
J ECT. 2016 Jun;32(2):75-7
pubmed: 27191123
Nat Rev Neurol. 2012 Dec;8(12):690-9
pubmed: 23147846
Neuroimage. 2016 Oct 15;140:4-19
pubmed: 26883069
Mov Disord. 2006 Dec;21(12):2206-8
pubmed: 17013907